secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001104659-22-058628
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing
--------------------------------------------------------------------------------

- Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.
- Cash, cash equivalents and short-term investments of $16.7M at March 31, 2022, up from $5.7M at Dec 31, 2021 due to IPO.
- R&D expenses $1.8M; G&A expenses $1.1M for the quarter.
- NXP800 Phase 1 dose escalation portion ongoing; presented at 2022 AACR 'New Drugs on the Horizon'.
- Completed IPO in Feb 2022 raising $16M gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/0001104659-22-058628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/tm2214978d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-058628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer